Salient features

Turnover increased 5% to
R2,25 billion

EBITDA decreased 15% to
R490 million

HEPS decreased 10% to
198,7 cents

Dividend per share increased 6,2% to 86 cents

Cash on hand: R568 million

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The Company has a 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter brands. The Company is South Africa’s largest supplier of hospital and critical care products. Its footprint extends to India and other territories in sub-Saharan Africa.

The extensive product portfolio includes branded and generic prescription medicines and over-the-counter/fast moving consumer goods (FMCG) brands, intravenous solutions, blood collection products and renal dialysis systems.

Vision

To be recognised as a leading world-class branded healthcare company.

Commentary

FINANCIAL REVIEW

The six-month period under review saw Adcock Ingram facing several challenges, both internal and external, that tested the Company’s business model and strategy. Although the financial results achieved were disappointing, the Company continues to invest in its supply chain, products and people, all of which give confidence for improved future performance.

Headline earnings

The Company achieved headline earnings for the six months ended 31 March 2012 of R335,8 million. This represents a 12% decrease from the comparable figure for 2011 of R381,7 million. This translates into a decrease of 10,2% at the headline earnings per share (HEPS) level and 10,4% at the earnings per share (EPS) level.

	Consolidated statements of comprehensive income
	Consolidated statement of changes in equity
	Consolidated statements of financial position
	Consolidated abridged statements of cash flows
	Notes to the consolidated financial statements

Downloads

	Results booklet [PDF - 178KB]
	Presentation [PDF - 3MB]
	Webcast

	PDF downloads
	Excel Downloads

Salient features

Commentary

Financial Statements

Downloads